Cited by 207SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsT-cell and B-cell Immunology

The DOI matches its Crossref record; 52 of the 58 references it cites were found in a registry or an index.

Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine

Open access

Goel, Rishi R., Painter, Mark M., Lundgreen, Kendall A., Apostolidis, Sokratis A., Baxter, Amy E., Giles, Josephine R., Mathew, Divij, Pattekar, Ajinkya, Reynaldi, Arnold, Khoury, David S., Gouma, Sigrid, Hicks, Philip, Dysinger, Sarah, Hicks, Amanda, Sharma, Harsh, Herring, Sarah, Korte, Scott, KC, Wumesh, Oldridge, Derek A., Erickson, Rachel I., Weirick, Madison E., McAllister, Christopher M., Awofolaju, Moses, Tanenbaum, Nicole, Dougherty, Jeanette, Long, Sherea, D’Andrea, Kurt, Hamilton, Jacob T., McLaughlin, Maura, Williams, Justine C., Adamski, Sharon, Kuthuru, Oliva, Drapeau, Elizabeth M., Davenport, Miles P., Hensley, Scott E., Bates, Paul, Greenplate, Allison R., Wherry, E. John·2022·Cell

DOI 10.1016/j.cell.2022.04.009PMC PMC8989683

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

We examined antibody and memory B cell responses longitudinally for ∼9-10 months after primary 2-dose SARS-CoV-2 mRNA vaccination and 3 months after a 3rd dose. Antibody decay stabilized between 6 and 9 months, and antibody quality continued to improve for at least 9 months after 2-dose vaccination. Spike- and RBD-specific memory B cells remained durable over time, and 40%-50% of RBD-specific memory B cells simultaneously bound the Alpha, Beta, Delta, and Omicron variants. Omicron-binding memory B cells were efficiently reactivated by a 3rd dose of wild-type vaccine and correlated with the corresponding increase in neutralizing antibody titers. In contrast, pre-3rd dose antibody titers inversely correlated with the fold-change of antibody boosting, suggesting that high levels of circulating antibodies may limit the added protection afforded by repeat short interval boosting. These data provide insight into the quantity and quality of mRNA-vaccine-induced immunity over time through 3 or more antigen exposures.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2022.04.009

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Self-citation
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 1×
“Antigen-specific B cell responses were quantified from bulk PBMCs by flow cytometry using fluorescently labeled SARSCoV-2 spike and RBD probes as previously described (Dan et al., 2021; Goel et al., 2021b, 2021a).”
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992 · cited 2×
“Of these VOC, the Delta (B.1.617.2) variant had considerable impact due to its increased infectivity and partial escape from neutralizing antibodies (Mlcochova et al., 2021; Planas et al., 2021).”
Influential
Germinal Centers
Victora, G. D., & Nussenzweig, M. C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075032 · Cited by 1,878
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R. P. E. S., Moyo, S. M., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04411-y · Cited by 1,674
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Self-citation
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337

Flagged first, then by citations

Show all 58 references

6 of the 58 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Cele, 2021, Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization, Nature, 602, 654, 10.1038/s41586-021-04387-1 · DOI · Paper page
Shrestha, 2022, Coronavirus disease 2019 (COVID-19) vaccine boosting in persons already protected by natural or vaccine-induced immunity, J. Neurol. Sci., 428, 117607

Sorted by citations

Items 101–200 of 207

Arming up against Omicron subvariants
Altmann, D. M., & Boyton, R. J. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.010 · Cited by 8
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant
Pastore, G., Polvere, J., Fiorino, F., Lucchesi, S., Montesi, G., Rancan, I., Zirpoli, S., Lippi, A., Durante, M., Fabbiani, M., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2333952 · Cited by 8
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program
van Leeuwen, L. P. M., Grobben, M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., van Gils, M. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1390022 · Cited by 8
Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants
Shrestha, L. B., Tungatt, K., Aggarwal, A., Stubis, A., Fewings, N., Fichter, C., Akerman, A., Rodrigo, C., Tedla, N. T., Lee, S. C. L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105461 · Cited by 8
Exponential decline, ceiling effect, downregulation, and T-cell response in immunoglobulin G antibody levels after messenger RNA vaccine boosters: a case report
Hirano, H., & Asada, H. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04889-2 · Cited by 8
Bivalent mRNA booster vaccination recalls cellular and antibody immunity against antigenically divergent SARS-CoV-2 spike antigens
Trieu, M.-C., Reynaldi, A., Lee, W. S., Tan, H., Kelly, A. P., Esterbauer, R., Cox, R. J., Audsley, J., Sasadeusz, J., Khoury, D. S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01129-6 · Cited by 8
Self-citation
Long‐term immune response to Omicron‐specific mRNA vaccination in mice, hamsters, and nonhuman primates
Wu, Y., Wu, N., Jia, X., Wu, Y., Zhang, X., Liu, Y., Hou, Y., Shen, Y., Li, E., Wang, W., et al. (2023) · MedComm · doi:10.1002/mco2.460 · Cited by 7
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination
Lapointe, H. R., Mwimanzi, F. M., Cheung, P. K., Sang, Y., Yaseen, F., Kalikawe, R., Datwani, S., Waterworth, R., Umviligihozo, G., Ennis, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947021 · Cited by 7
Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases
Liu, Y., Lu, J., Zhan, H., Yuan, W., Li, X., Kang, H., Li, H., Chen, Y., Cheng, L., Sun, X., et al. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.07.005 · Cited by 7
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic
Molinos-Albert, L. M., Rubio, R., Martín-Pérez, C., Pradenas, E., Torres, C., Jiménez, A., Canyelles, M., Vidal, M., Barrios, D., Marfil, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115498 · Cited by 7
The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity
Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J. J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911325 · Cited by 39
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
Vargas‐Herrera, N., Fernández-Navarro, M., Cabezudo, N. E., Soto-Becerra, P., Solis, G., Escobar-Agreda, S., Valencia, J. S., Pampa-Espinoza, L., Bado, R., Solari, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268419 · Cited by 8
Analysis of Antigen‐Specific T and B Cells for Monitoring Immune Protection Against SARS‐CoV‐2
Biasi, S. D., Paolini, A., Tartaro, D. L., Gibellini, L., & Cossarizza, A. (2023) · Current Protocols · doi:10.1002/cpz1.636 · Cited by 7
Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines
Wang, J., Huang, L., Guo, N., Yao, Y., Zhang, C., Xu, R., Jiao, Y., Li, Y.-Q., Song, Y.-R., Wang, F., et al. (2023) · Viruses · doi:10.3390/v15040917 · Cited by 7
Progress in vaccine development for infectious diseases—a Keystone Symposia report
Cable, J., Graham, B. S., Koup, R. A., Seder, R. A., Karikó, K., Pardi, N., Barouch, D. H., Sharma, B., Rauch, S., Nachbagauer, R., et al. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14975 · Cited by 8
Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodiesPreprint
Painter, M. M., Johnston, T. S., Lundgreen, K. A., Santos, J. J. D. S., Qin, J. S., Goel, R. R., Apostolidis, S. A., Mathew, D., Fulmer, B., Williams, J. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.05.527215 · Cited by 7
Self-citation
A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile
Sannier, G., Nicolas, A., Dubé, M., Marchitto, L., Nayrac, M., Tastet, O., Chatterjee, D., Tauzin, A., Lima-Barbosa, R., Laporte, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100955 · Cited by 6
Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
Chang, X., Liu, X., Martina, B. E. E., Zeltiņš, A., Augusto, G. S., Vogel, M., Mohsen, M. O., Speiser, D. E., & Bachmann, M. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1114396 · Cited by 5
Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy
Choi, M. J., Hyun, H., Heo, J. Y., Seo, Y. B., Noh, J. Y., Cheong, H. J., Kim, W. J., Kim, H. J., Choi, J., Lee, Y. J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27211 · Cited by 8
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Poh, X. Y., Lee, I. R., Tan, C. W., Chavatte, J., Fong, S., Goh, Y. S., Rouers, A., Wong, N., Torres‐Ruesta, A., Mah, S. Y. Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105275 · Cited by 6
Effectiveness of COVID-19 Vaccination In Healthcare Workers in Shiga Prefecture, Japan
Chano, T., Yamashita, T., Fujimura, H., Kita, H., Ikemoto, T., Kume, S., Morita, S., Suzuki, T., & Kakuno, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-22682-3 · Cited by 6
Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
Prusinkiewicz, M. A., Sediqi, S., Li, Y. J., Goldfarb, D. A., Asamoah-Boaheng, M., Wall, N., Lavoie, P. M., & Grunau, B. E. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17259 · Cited by 6
Efficient recall of SARS‐CoV‐2 variant‐reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters
Rouers, A., Wong, N., Goh, Y. S., Torres‐Ruesta, A., Tay, M. Z., Chang, Z. W., Fong, S., Neo, V. K., Kam, I. K. J., Yeo, N. K., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28258 · Cited by 5
Protective Effect of Vaccine Doses and Antibody Titers Against SARS-CoV-2 Infection in Kidney Transplant Recipients
Chen, C., Hsu, M.-K., Huang, Y., Lai, M.-J., Wu, S.-W., Lin, M.-H., Hung, H.-S., Lin, Y.-C., Huang, Y., Lee, Y.-F., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11196 · Cited by 6
Third dose COVID-19 mRNA vaccine enhances IgG4 isotype switching and recognition of Omicron subvariants by memory B cells after mRNA but not adenovirus primingPreprint
Hartley, G. E., Fryer, H. A., Gill, P. A., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., Edwards, E. S. J., & van Zelm, M. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557929 · Cited by 6
Germinal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination
Kim, W. (2024) · Immune Network · doi:10.4110/in.2024.24.e28 · Cited by 5
mRNA prime-boost vaccination promotes clonal continuity in germinal center reactions and broadens SARS-CoV-2 variant coverage
Ciancaglini, M., Fixemer, J., Seven, C., Dimitrova, M., Finozzi, D., Weklak, D., Kastner, A. L., Jönsson, F., Wagner, I., Vincenti, I., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.008 · Cited by 6
Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Vanetti, C., Stracuzzi, M., Crivellaro, E., Ciciliano, F., Garziano, M., Fenizia, C., Biasin, M., Rubinacci, V., Amendola, A., Tanzi, E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301766 · Cited by 5
Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamsters
Patel, R. S., Duque, D., Bavananthasivam, J., Hewitt, M., Sandhu, J. K., Kumar, R. K., Tran, A., & Agrawal, B. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlae011 · Cited by 5
Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19
Kumar, D., Gaikwad, K., Gunnale, R., Vishwakarma, S., Shukla, S., Srivastava, S., Gopal, J., Vaidya, B., Saraf, A., Gurjar, R., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01076-2 · Cited by 5
Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study
Kwesi‐Maliepaard, E. M., Alhassan, Y., Quaye, E. K., Kotey, V. M., Mohammed, A. M., Agyemang, S., Sromani, A. K., Darko, S., Buadii, E., Tackie, R., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04157-0 · Cited by 5
Identification of B cell subsets based on antigen receptor sequences using deep learning
Lee, H., Shin, K., Lee, Y., Lee, S., Lee, S., Lee, E., Kim, S. W., Shin, H. Y., Kim, J. H., Chung, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342285 · Cited by 7
Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
Yi, Y., Han, X., Cui, X., Wang, P., Wang, X., Liu, H., Wang, Y., Zhu, N., Li, Y., Lin, Y., et al. (2023) · Vaccines · doi:10.3390/vaccines11061019 · Cited by 5
COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022Preprint
Braeye, T., van Loenhout, J. A. F., Brondeel, R., Stouten, V., Hubin, P., Billuart, M., Chung, J., Vandromme, M., Wyndham-Thomas, C., Blot, K. Y., et al. (2022) · medRxiv · doi:10.1101/2022.05.09.22274623 · Cited by 5
Omicron BA.1 breakthrough infection drives long-term remodeling of the memory B cell repertoire in vaccinated individualsPreprint
Sokal, A., Spaeth, G. B., Hunault, L., Fernández, I., Broketa, M., Meola, A., Fourati, S., Azzaoui, I., Vandenberghe, A., Lagouge-Roussey, P., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.27.525575 · Cited by 5
Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice
Wiatr, M., wang, Z., Canis, M., Hernandez, B., Gazumyan, A., Santos, G. S. S., Shawraz, S., lee, S., Bieniasz, P. D., Hatziioannou, T., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2527869123 · Cited by 4
Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication
Lenart, K., Feuerstein, H., Marmorato, M. P., Vidakovics, L. P., McInerney, G. M., Guebre‐Xabier, M., Trost, J. F., Eriksson, B., Smith, G., Patel, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60885-0 · Cited by 4
A consensus mathematical model of vaccine-induced antibody dynamics for multiple vaccine platforms and pathogens
Wilding, K. M., Molina-Parı́s, C., Kubicek-Sutherland, J. Z., McMahon, B. H., Perelson, A. S., & Ribeiro, R. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1596518 · Cited by 5
Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans
Khurana, S., Posadas, O., Kardava, L., Coyle, E. M., Ravichandran, S., Grubbs, G., McConnell, R., Rouphael, N., Poliquin, G., Langley, J. M., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02459-w · Cited by 4
New boosters are here! Who should receive them and when?
Doron, S., & Gandhi, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00688-0 · Cited by 4
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease
Connolly, C. M., Frey, S. M., Chiang, T. P., Teles, M. S., Alejo, J. L., Albayda, J., Shah, A. A., Werbel, W. A., Segev, D. L., Christopher‐Stine, L., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac298 · Cited by 4
Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, JapanPreprint
Nakamura, N., Kobashi, Y., Kim, K. S., Tani, Y., Shimazu, Y., Zhao, T., Nishikawa, Y., Omata, F., Kawashima, M., Yoshida, M., et al. (2022) · medRxiv · doi:10.1101/2022.06.11.22276266 · Cited by 3
Longitudinal changes in IgG-type SARS-CoV-2 antibody titers after COVID-19 vaccination and, prominent increase in antibody titers when infected after vaccinationPreprint
Kusunoki, H., Ohkusa, M., Iida, R., Saito, A., Kawahara, M., Ekawa, K., Kato, N., Yamasaki, K., Motone, M., & Shimizu, H. (2023) · medRxiv · doi:10.1101/2023.02.04.23285414 · Cited by 4
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster
Wachter, B. T., Xu, Q., Shi, L., Burbelo, P. D., Myint-Hpu, K., Schwartzberg, P. L., Rehman, M. T., Dewar, R. L., Boswell, K. L., Koup, R. A., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.02.026 · Cited by 4
Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
Augello, M., Bono, V., Rovito, R., Tavelli, A., Santoro, A., Tincati, C., Vergori, A., Azzini, A. M., Righi, E., Spiteri, G., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00799-6 · Cited by 3
Mixed lipopeptide-based mucosal vaccine elicits a long-term bone marrow memory response that is potentially cross-reactive against a broad-spectrum of coronaviruses in mice
Patel, R. S., & Agrawal, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619882 · Cited by 3
B-Cell Responses to Sars-Cov-2 mRNA Vaccines
Kardava, L., Buckner, C. M., & Moir, S. L. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.550 · Cited by 3
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV
Mkhize, N. N., Zhang, B., Brackett, C., Elyanu, P., Tapley, A., Dadabhai, S. S., Hu, J., Do, B. T. N., Schuster, D. J., Heptinstall, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63948-4 · Cited by 3
Effect of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster on Human Immunodeficiency Virus Reservoirs and Immune Markers
Ali, M., Shi, V., Kennedy, B. D., Justement, J. S., Gittens, K. R., McCormack, G. E., Blažková, J., Moir, S. L., & Chun, T. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac544 · Cited by 3
Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain
Wang, Q., Wang, S., Liu, Y., Wang, S., Peng, H., Hao, Y., Hong, K., Li, D., & Shao, Y. (2023) · Pathogens · doi:10.3390/pathogens12050655 · Cited by 3
Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy
Priddey, A. J., Chen-Xu, M., Cooper, D. J., MacMillan, S., Meisl, G., Xu, C. K., Hosmillo, M. D. T., Goodfellow, I., Kollyfas, R., Döffinger, R., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296148 · Cited by 4
Essential role of CD56dimNKG2C+ NK cells trained by SARS-CoV-2 vaccines in protecting against COVID-19
Zheng, H., Chen, Y., Li, J., Zhang, Y., Li, H., Zhao, X., He, Z., Liao, Y., Zhang, Z., Shi, H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.031 · Cited by 2
Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers
Ikezaki, H., Nomura, H., & Shimono, N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12125 · Cited by 3
Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2Preprint
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H., Au, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.09.491254 · Cited by 3
Durable reprogramming of neutralising antibody responses following breakthrough Omicron infectionPreprint
Lee, W. S., Tan, H., Reynaldi, A., Esterbauer, R., Koutsakos, M., Nguyen, J. T., Amarasena, T. H., Kent, H. E., Aggarwal, A., Turville, S. G., et al. (2023) · medRxiv · doi:10.1101/2023.02.19.23286159 · Cited by 3
Self-citation
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Milojković, D., Reynolds, C. J., Sandoval, D. M., Pieper, F. P., Liu, S., Pade, C., Gibbons, J. M., McKnight, Á., Loaiza, S., Palanicawander, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01787-8 · Cited by 2
Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV
Polvere, J., Lucchesi, S., Montesi, G., Fiorino, F., Pastore, G., Fabbiani, M., Tumbarello, M., Montagnani, F., Medaglini, D., & Ciabattini, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07414-1 · Cited by 2
SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost
Lijeskić, O., Bauman, N., Marković, M., Srbljanović, J., Bobić, B., Zlatković, Đ., & Štajner, T. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.085 · Cited by 2
A polyvalent RNA vaccine reduces the immune imprinting phenotype in mice and induces neutralizing antibodies against omicron SARS-CoV-2
Rocha, V. P. C., Machado, B. A. S., Barreto, B. C., Quadros, H. C., Fernandes, A. M. S., Lima, E. D. S., Bandeira, M. E., Meira, C. S., Fonseca, L. M. D. S., Erasmus, J. H., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25539 · Cited by 2
Monitoring of antibodies against SARS-CoV-2 over 2 years and characterization of immune responses following Omicron infection in a South Indian community cohort
Madhavan, R., Gupta, D., Paul, J. S., Babji, S., Syed, C., Saravanan, P., Kumar, A., Immanuel, S., Gandhi, V., Eswaran, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-10447-7 · Cited by 2
Dynamics of SARS-CoV-2-Specific B Cell Memory Responses in Infected and Vaccinated Individuals
Fabiani, M., Margiotti, K., Monaco, F., Viola, A., Cima, A., Mesoraca, A., & Giorlandino, C. (2023) · Viral Immunology · doi:10.1089/vim.2022.0197 · Cited by 2
Limited enhancement of antibody and B‐cell responses to prototype booster vaccination following SARS‐CoV‐2 Delta breakthrough infection
Wang, X., He, X., Jiang, S., Fu, Z., Jiang, S., Zhao, X., Zhao, C., Li, Y., Li, D., Zhang, W., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28540 · Cited by 1
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
Laquintana, V., Mottini, C., Marchesi, F., Marcozzi, B., Terrenato, I., Sperandio, E., de Latouliere, L., Carrieri, F., Pimpinelli, F., Pontone, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221587 · Cited by 1
Relationship between B-Cell Populations, Development and Function of B-Cell Subsets
Mortari, E. P., & Carsetti, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95895-0.00022-2 · Cited by 1
Reading of human acute immune dynamics in omicron SARS-CoV-2 breakthrough infection
Li, H., Liu, H., Wu, H., Guo, C. M., Zuo, W., Zheng, Y., Deng, X., Xu, J., Wang, Y., Wang, Z., et al. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2494705 · Cited by 1
Herd Immunity to SARS-CoV-2 Among the Armenian Population in the Second Half of 2022
Popova, A. Y., Смирнов, В. С., Egorova, S. A., Melik-Andreasyan, G., Atoyan, S. A., Milichkina, A. M., Drozd, I. V., Palozyan, G. H., Ivanov, V. A., Ramsay, E. S., et al. (2025) · Epidemiologia · doi:10.3390/epidemiologia6030029 · Cited by 1
Quantification of the IgG antibody response half-life for hybrid immunity to SARS-CoV-2
Bongiovanni, F., Conway, E. J., Smith, L., Cumming, J., Mazhari, R., Kiernan‐Walker, N., Eriksson, E. M., McVernon, J., & Müeller, I. (2025) · BMC Medicine · doi:10.1186/s12916-025-04490-4 · Cited by 1
Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)–final report
Stemler, J., Yeghiazaryan, L., Stephan, C., Mohn, K. G.-I., Cox, R. J., Carcas, A. J., Rodríguez, E. M. R., Moltó, J., Mitxeltorena, I. V., Pink, I., et al. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108466 · Cited by 1
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost
Lima, N. S., McCormick, L., Li, S., Wake, C., Subramanian, R., Spangler, A., Pinto, Y., Catalano, W. L., Henry, A. R., Laboune, F., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aeb9837 · Cited by 1
Targeting T follicular helper cells for lifelong health
Linterman, M. A., Yu, D., Webb, L. M. C., & Vinuesa, C. G. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01495-3 · Cited by 1
Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients
Dimou, A. (2022) · Vaccines · doi:10.3390/vaccines10122117
The Dawn of Microbiology
Juhas, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-29544-7_2 · Cited by 1
Immunogenicity of BNT162b2 vaccine after two and three doses in health personnel and institutionalized elderly people not infected with SARS-CoV-2
Rodríguez-Prieto, M., Modino-García, F., de la Arada-Benavides, C., de la Puente, R., Carvajal, A., Rodríguez-Cabañeros, I., de Prado-Santos, C., de Mota-Luna, B., Fernández‐Villa, T., Fernández-Vázquez, J. P., et al. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102092 · Cited by 2
Durability of immune response against omicron BA.2 and BA.4/5 and T cell responses after boosting with mRNA and adenoviral vector-based vaccines following heterologous CoronaVac/ChAdOx-1nCov-19 vaccination
Suntronwong, N., Kanokudom, S., Thatsanathorn, T., Thongmee, T., Sudhinaraset, N., Wanlapakorn, N., & Poovorawan, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2283916 · Cited by 1
Blended BA.5 infection within 8 days after a boosted bivalent mRNA vaccination strengthens and lengthens the host immunity
Huang, M., Cui, T., Liu, S., Su, X., Wang, Y., Wang, J., Zhong, J., Cao, J., Mei, X., Li, K., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29544 · Cited by 1
Diverse BCR usage and T cell activation induced by different COVID-19 sequential vaccinations
Wang, J., Li, K., Wang, Y., Lin, Z., Li, W., Cao, J., Mei, X., Wei, R., Yang, J.-L., Zhai, X., et al. (2024) · mBio · doi:10.1128/mbio.01429-24 · Cited by 1
The type of the first prime/boost vaccine against SARS-CoV-2 exerts long-term effects on the humoral immune response
Mai, F., Reisinger, E. C., & Müller‐Hilke, B. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110523 · Cited by 1
Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infectionPreprint
Seow, J., Shalim, Z. A., Graham, C., Kimuda, S., Pillai, A., Lechmere, T., Kurshan, A., Khimji, A. M., Snell, L., Nebbia, G., et al. (2023) · bioRxiv · doi:10.1101/2023.03.30.534872 · Cited by 1
Three-Dose Vaccination-Induced Immune Responses Protect Against SARS-CoV-2 Omicron BA.2Preprint
Zhou, R., Liu, N., Li, X., Peng, Q., Yiu, C.-K., Huang, H., Yang, D., Du, Z., Kwok, H., Au, K., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4123263
Effectiveness of COVID-19 Vaccination In Healthcare Workers in Shiga Prefecture, JapanPreprint
Chano, T., Yamashita, T., Fujimura, H., Kita, H., Ikemoto, T., Kume, S., Morita, S., Suzuki, T., & Kakuno, F. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4149842
Double-dose mRNA vaccination to SARS-CoV-2 progressively increases recognition of variants-of-concern by Spike RBD-specific memory B cellsPreprint
Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Aui, P. M., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502703
The response to BTN62b2 booster doses demonstrates that serum antibodies do not predict the establishment of immune B-cell memory in common variable immune deficienciesPreprint
Mortari, E. P., Pulvirenti, F., Marcellini, V., Terreri, S., Salinas, A. F., Ferrari, S., Napoli, G. D., Guadagnolo, D., Sculco, E., Albano, C., et al. (2022) · medRxiv · doi:10.1101/2022.12.24.22283775
The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule
Naidich, G., Santucci, N. E., Pezzotto, S. M., Ceccarelli, E. A., Bottasso, O. A., & Perichón, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141794
COVID-19
Juhas, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-29544-7_10
Mutational basis of serum cross-neutralization profiles elicited by infection or vaccination with SARS-CoV-2 variantsPreprint
Wagh, K., Shen, X., Theiler, J. P., Girard, B., Marshall, J.-C. A., Montefiori, D. C., & Korber, B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.13.553144
Vacunaciones
Beytout, J. (2023) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(23)48480-2
B Cell Subtypes in Individuals Received mRNA or Inactivated Vaccine Boosters After Fully Vaccinated with CoronaVac: A Longitudinal Study
Kuloğlu, Z. E., Talay, Z. G., Albayrak, Ö., Ergönül, Ö., & Can, F. (2023) · Infectious Diseases and Clinical Microbiology · doi:10.36519/idcm.2023.246
Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine
Haralambieva, I. H., Monroe, J. M., Ovsyannikova, I. G., Warner, N. D., Grill, D. E., Poland, G. A., & Kennedy, R. B. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.032
Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine
Yasri, S., & Wiwanitkit, V. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0043-1774328
Impact of Anti-SARS-CoV-2 Vaccination on Disease Severity and Clinical Outcomes of Individuals Hospitalized for COVID-19 Throughout Successive Pandemic Waves: Data from an Italian Reference Hospital
Mondi, A., Mastrorosa, I., Navarra, A., Cimaglia, C., Pinnetti, C., Mazzotta, V., Agresta, A., Corpolongo, A., Zolezzi, A., Moghazi, S. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12091018 · Cited by 1
Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort
Sheehan, J., Trauth, A. J., Hagensee, M. E., & Ramsay, A. J. (2025) · Pathogens · doi:10.3390/pathogens14010044
Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters
Ahmed, J. I., Krosta, S. J., Reimer, M. N., Cheung, W., Mesa, C., Lopez, C., Chua, R. J., Alsattari, F., Robinson, A., Manguiat, K., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529134
Effects of booster vaccination on post-treatment oxygen deterioration in hospitalized mild-to-moderate COVID-19 Japanese patients with comorbidities during the Omicron wave
Hayai, S., Fukumitsu, K., Suzuki, A., Fukihara, J., Katano, T., Yonezawa, T., Ogisu, T., Tanaka, H., Inoue, T., Kako, H., et al. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102764
Antibody and B‐Cell Responses to PHH‐1V81 XBB.1.16‐Adapted SARS‐CoV‐2 Booster Vaccination Are Associated With Variant Neutralization
Torres, C., Jiménez, A., Deulofeu, M., Prenafeta, A., Dobaño, C., Moncunill, G., Ferrer, L., & Molinos-Albert, L. M. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70583
DynPerturb:Dynamic Perturbation Modeling for Spatiotemporal Single-Cell SystemsPreprint
Qin, H., Zhang, Y., Guo, Z., Hu, L., Li, Q., Cao, L., Xia, T., Deng, Z., Zhang, Y., Li, Y. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.15.676236
Pre-Omicron Immunity Generates IgG⁺ but Not IgA⁺ Memory B Cells Reactive to Omicron Spike ProteinPreprint
Tsoleridis, T., Singh, I., Onion, D., Chappell, J. G., Kelly, A., Nightingale, J., Valdes, A. M., Ollivere, B. J., Hoehn, K. B., Urbanowicz, R. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678818
Predicting long-term waning of anti-spike antibody-dependent protection against COVID-19 across diverse SARS-CoV-2 immune historiesPreprint
Numakura, K., Miyamoto, S., Sataka, A., Takeyama, H., & Suzuki, T. (2025) · medRxiv · doi:10.1101/2025.11.14.25340279
Symptom progression and viral shedding dynamics in children and adolescents with asymptomatic and mild COVID-19 infections
Yang, P., Jiang, X., Zhang, Y., Kang, W., Liu, Y., Gang, Y., Li, R., Wang, W., Wang, T., Zhang, W., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12828-3
Flow Cytometric Assessment of Pertactin- and Tetanus Toxoid-Specific B-Cell Kinetics After Tdap Booster Vaccination in Healthy Adults
Esser, M. J., Diks, A. M., Oosten, L. E. M., Groenland, R. J., de Mooij, B., Teodósio, C., Driessen, G. J. A., van Dongen, J. J. M., & Berkowska, M. A. (2026) · Vaccines · doi:10.3390/vaccines14040297
Caractérisation de la réponse lymphocytaire B mémoire contre le SARS-CoV-2 après infection ou vaccination
Sokal, A. (2022) · theses.fr (ABES) · doi:10.70675/00bd0a63z263fz470az876czb50b49ba4313

Authors: Goel, R. R., Painter, M. M., Lundgreen, K. A., Apostolidis, S. A., Baxter, A. E., Giles, J. R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D. S., Gouma, S., Hicks, P., Dysinger, S., Hicks, A., Sharma, H., Herring, S., Korte, S., KC, W., Oldridge, D. A., Erickson, R. I., Weirick, M. E., McAllister, C. M., Awofolaju, M., Tanenbaum, N., Dougherty, J., Long, S., D’Andrea, K., Hamilton, J. T., McLaughlin, M., Williams, J. C., Adamski, S., Kuthuru, O., Drapeau, E. M., Davenport, M. P., Hensley, S. E., Bates, P., Greenplate, A. R., & Wherry, E. J.
Affiliations: University of Pennsylvania (US)
Parker Institute for Cancer Immunotherapy (US)
UNSW Sydney (AU)
Corresponding author: Wherry, E. John
ORCID: Goel, Rishi R.
Painter, Mark M.
Lundgreen, Kendall A.
Apostolidis, Sokratis A.
Baxter, Amy E.
Giles, Josephine R.
Mathew, Divij
Pattekar, Ajinkya
Reynaldi, Arnold
Khoury, David S.
Gouma, Sigrid
Hicks, Philip
Dysinger, Sarah
Sharma, Harsh
Herring, Sarah
Korte, Scott
Oldridge, Derek A.
Erickson, Rachel I.
Weirick, Madison E.
McAllister, Christopher M.
Awofolaju, Moses
Tanenbaum, Nicole
Dougherty, Jeanette
Long, Sherea
Hamilton, Jacob T.
Williams, Justine C.
Adamski, Sharon
Kuthuru, Oliva
Drapeau, Elizabeth M.
Davenport, Miles P.
Hensley, Scott E.
Bates, Paul
Greenplate, Allison R.
Wherry, E. John
Venue: Cell
Publisher: Elsevier BV
Published: 2022-05
Volume: 185
Issue: 11
Pages: 1875-1887.e8
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2022.04.009
PMC: PMC8989683
OpenAlex: W4225964771
Cited by: 207
References: 58
Citations by year: 2026: 15 · 2025: 31 · 2024: 33 · 2023: 70 · 2022: 58
FWCI: 23.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 390 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
PubMed Central (submittedVersion, cc-by-nd)
Funders: National Institutes of Health (T32 AI055400, T32 CA009140, T32 AR076951-01, AI155577, AI108545, P30CA016520, AI142638, U19AI082630, AI152236, AI149680, 75N93021C00015, HL143613)
Perelman School of Medicine, University of Pennsylvania
Paul and Daisy Soros Fellowships for New Americans
Australian Research Council
Parker Institute for Cancer Immunotherapy
NHMRC (GNT1149990)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: COVID-19 mRNA vaccine, Omicron variant, memory B cells, antibody waning, neutralizing antibodies, spike protein, receptor binding domain, antibody quality, vaccine-induced immunity, antibody boosting, long-term antibody persistence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks